ViewRay Announces Conference Call for Preliminary First Quarter 2023 Financial Results to be held Pre-Market opening on April 13, 2023

DENVER, April 12, 2023

After the live webcast, a replay will remain available online on the investor relations page of ViewRay's website under "Events and Webinars".

About ViewRay^®

ViewRay, Inc. (Nasdaq: VRAY) designs, manufactures, and markets the MRIdian® MR-Guided Radiation Therapy System. MRIdian is built upon a proprietary high-definition MR imaging system designed from the ground up to address the unique challenges and clinical workflow for advanced radiation oncology. Unlike MR systems used in diagnostic radiology, MRIdian's high-definition MR was purpose-built to address specific challenges, including beam distortion, skin toxicity, and other concerns that potentially may arise when high magnetic fields interact with radiation beams. ViewRay and MRIdian are registered trademarks of ViewRay, Inc.

View original content:https://www.prnewswire.com/news-releases/viewray-announces-conference-call-for-preliminary-first-quarter-2023-financial-results-to-be-held-pre-market-opening-on-april-13-2023-301796074.html

SOURCE ViewRay, Inc.